Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 32
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Biochem Mol Toxicol ; 38(3): e23661, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38369721

RESUMO

Phenothiazines (PTZs) are an emerging group of molecules showing effectiveness toward redox signaling and reduction of oxidative injury to cells, via the activation on Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2 (Nrf2). Although several electrophilic and indirect Nrf2 activators have been reported, the risk of "off-target" effect due to the complexity of their molecular mechanisms of action, has aroused research interest toward non-electrophilic and direct modulators of Nrf2 pathway, such as PTZs. This review represents the first overview on the roles of PTZs as non-electrophilic Nrf2 activator and free radical scavengers, as well as on their potential therapeutic effects in oxidative stress-mediated diseases. Here, we provide a collective and comprehensive information on the PTZs ability to scavenge free radicals and activate the Nrf2 signaling pathway, with the aim to broaden the knowledge of their therapeutic potentials and to stimulate innovative research ideas.


Assuntos
Antioxidantes , Fator 2 Relacionado a NF-E2 , Fenotiazinas , Antioxidantes/farmacologia , Antioxidantes/metabolismo , Sequestradores de Radicais Livres , Proteína 1 Associada a ECH Semelhante a Kelch/metabolismo , Fator 2 Relacionado a NF-E2/metabolismo , Estresse Oxidativo , Transdução de Sinais , Fenotiazinas/farmacologia
2.
Int J Mol Sci ; 24(4)2023 Feb 11.
Artigo em Inglês | MEDLINE | ID: mdl-36835033

RESUMO

3-3'-Diindolylmethane (DIM) is a biologically active dimer derived from the endogenous conversion of indole-3-carbinol (I3C), a naturally occurring glucosinolate found in many cruciferous vegetables (i.e., Brassicaceae). DIM was the first pure androgen receptor antagonist isolated from the Brassicaceae family and has been recently investigated for its potential pharmacological use in prostate cancer prevention and treatment. Interestingly, there is evidence that DIM can also interact with cannabinoid receptors. In this context, by considering the well-known involvement of the endocannabinoid system in prostate cancer, we have pharmacologically characterized the properties of DIM on both CB1 and CB2 cannabinoid receptors in two human prostate cancer cell lines: PC3 (androgen-independent/androgen receptor negative) and LNCaP (androgen-dependent). In the PC3 cell line, DIM was able to activate CB2 receptors and potentially associated apoptotic pathways. On the other hand, although DIM was also able to activate CB2 receptors in the LNCaP cell line, no apoptotic effects were observed. Our evidence confirms that DIM is a CB2 receptor ligand and, moreover, it has a potential anti-proliferative effect on androgen-independent/androgen receptor-negative prostate cancer cells.


Assuntos
Brassicaceae , Neoplasias da Próstata , Receptor CB2 de Canabinoide , Humanos , Masculino , Androgênios/metabolismo , Brassicaceae/química , Linhagem Celular , Neoplasias da Próstata/metabolismo , Receptores Androgênicos/metabolismo , Receptor CB2 de Canabinoide/agonistas , Receptor CB2 de Canabinoide/química
3.
Int J Mol Sci ; 24(2)2023 Jan 09.
Artigo em Inglês | MEDLINE | ID: mdl-36674826

RESUMO

In this study, we have investigated a possible mechanism that enables CB1/M3 receptor cross-talk, using SH-SY5Y cells as a model system. Our results show that M3 receptor activation initiates signaling that rapidly upregulates the CNR1 gene, resulting in a greatly potentiated CB1 receptor response to agonists. Calcium homeostasis plays an essential intermediary role in this functional CB1/M3 receptor cross-talk. We show that M3 receptor-triggered calcium release greatly increases CB1 receptor expression via both transcriptional and translational activity, by enhancing CNR1 promoter activity. The co-expression of M3 and CB1 receptors in brain areas such as the nucleus accumbens and amygdala support the hypothesis that the altered synaptic plasticity observed after exposure to cannabinoids involves cross-talk with the M3 receptor subtype. In this context, M3 receptors and their interaction with the cannabinoid system at the transcriptional level represent a potential pharmacogenomic target not only for the develop of new drugs for addressing addiction and tolerance. but also to understand the mechanisms underpinning response stratification to cannabinoids.


Assuntos
Canabinoides , Neuroblastoma , Humanos , Receptor CB1 de Canabinoide/genética , Receptor CB1 de Canabinoide/metabolismo , Cálcio/metabolismo , Canabinoides/farmacologia , Canabinoides/metabolismo , Sinalização do Cálcio
4.
Methods Mol Biol ; 2576: 111-118, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36152180

RESUMO

Displacement binding assays are nonfunctional assays mostly used with the aim of determining whether a certain compound (plant-derived or synthetic) can bind to a specific receptor with high affinity. Here, we describe the displacement binding assay that is carried out with a radioligand and CHO (Chinese Hamster Ovarian) cells stably transfected with the human cannabinoid CB2 receptor.


Assuntos
Bioensaio , Canabinoides , Animais , Células CHO , Canabinoides/metabolismo , Cricetinae , Cricetulus , Humanos , Ensaio Radioligante , Receptor CB2 de Canabinoide/genética , Receptores de Canabinoides
5.
Methods Mol Biol ; 2576: 171-179, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36152185

RESUMO

The cyclic AMP assay is a functional assay that is commonly used to determine the pharmacological behavior (agonists, antagonists, and inverse agonists) of G-protein coupled receptor ligands. Here, we describe the cyclic AMP assay that is carried out with commercially available nonradioligand ready-to-use kits and CHO (Chinese Hamster Ovarian) cells stably transfected with the human cannabinoid CB2 receptor.


Assuntos
Canabinoides , AMP Cíclico , Animais , Células CHO , Cricetinae , Cricetulus , Humanos , Ligantes , Receptor CB2 de Canabinoide/genética , Receptores de Canabinoides
6.
Mol Psychiatry ; 26(6): 2263-2276, 2021 06.
Artigo em Inglês | MEDLINE | ID: mdl-32203157

RESUMO

Excessive alcohol intake is associated with 5.9% of global deaths. However, this figure is especially acute in men such that 7.6% of deaths can be attributed to alcohol intake. Previous studies identified a significant interaction between genotypes of the galanin (GAL) gene with anxiety and alcohol abuse in different male populations but were unable to define a mechanism. To address these issues the current study analysed the human UK Biobank cohort and identified a significant interaction (n = 115,865; p = 0.0007) between allelic variation (GG or CA genotypes) in the highly conserved human GAL5.1 enhancer, alcohol intake (AUDIT questionnaire scores) and anxiety in men. Critically, disruption of GAL5.1 in mice using CRISPR genome editing significantly reduced GAL expression in the amygdala and hypothalamus whilst producing a corresponding reduction in ethanol intake in KO mice. Intriguingly, we also found the evidence of reduced anxiety-like behaviour in male GAL5.1KO animals mirroring that seen in humans from our UK Biobank studies. Using bioinformatic analysis and co-transfection studies we further identified the EGR1 transcription factor, that is co-expressed with GAL in amygdala and hypothalamus, as being important in the protein kinase C (PKC) supported activity of the GG genotype of GAL5.1 but less so in the CA genotype. Our unique study uses a novel combination of human association analysis, CRISPR genome editing in mice, animal behavioural analysis and cell culture studies to identify a highly conserved regulatory mechanism linking anxiety and alcohol intake that might contribute to increased susceptibility to anxiety and alcohol abuse in men.


Assuntos
Bancos de Espécimes Biológicos , Repetições Palindrômicas Curtas Agrupadas e Regularmente Espaçadas , Consumo de Bebidas Alcoólicas/genética , Animais , Ansiedade/genética , Etanol , Masculino , Camundongos , Reino Unido
7.
Bioorg Med Chem ; 28(11): 115513, 2020 06 01.
Artigo em Inglês | MEDLINE | ID: mdl-32340793

RESUMO

Focusing on the importance of the free phenolic hydroxyl moiety, a family of 23 alkylresorcinol-based compounds were developed and evaluated for their cannabinoid receptor binding properties. The non-symmetrical hexylresorcinol derivative 29 turned out to be a CB2-selective competitive antagonist/inverse agonist endowed with good potency. Both the olivetol- and 5-(2-methyloctan-2-yl)resorcinol-based derivatives 23 and 24 exhibited a significant antinociceptive activity. Interestingly, compound 24 proved to be able to activate both cannabinoid and TRPV1 receptors. Even if cannabinoid receptor subtype selectivity remained a goal only partially achieved, results confirm the validity of the alkylresorcinol nucleus as skeleton for the identification of potent cannabinoid receptor modulators.


Assuntos
Amidas/farmacologia , Analgésicos/farmacologia , Receptores de Canabinoides/metabolismo , Resorcinóis/farmacologia , Amidas/síntese química , Amidas/química , Analgésicos/síntese química , Analgésicos/química , Animais , Linhagem Celular , Relação Dose-Resposta a Droga , Humanos , Masculino , Camundongos , Estrutura Molecular , Ratos , Resorcinóis/química , Relação Estrutura-Atividade , Canais de Cátion TRPV/metabolismo
8.
Cell Commun Signal ; 17(1): 40, 2019 05 02.
Artigo em Inglês | MEDLINE | ID: mdl-31046795

RESUMO

Retinoic acid (RA) is the active metabolite of vitamin A and essential for many physiological processes, particularly the induction of cell differentiation. In addition to regulating genomic transcriptional activity via RA receptors (RARs) and retinoid X receptors (RXRs), non-genomic mechanisms of RA have been described, including the regulation of ERK1/2 kinase phosphorylation, but are poorly characterised. In this study, we test the hypothesis that genomic and non-genomic mechanisms of RA are regulated independently with respect to the involvement of ligand-dependent RA receptors. A panel of 28 retinoids (compounds with vitamin A-like activity) showed a marked disparity in genomic (gene expression) versus non-genomic (ERK1/2 phosphorylation) assays. These results demonstrate that the capacity of a compound to activate gene transcription does not necessarily correlate with its ability to regulate a non-genomic activity such as ERK 1/2 phosphorylation. Furthermore, a neurite outgrowth assay indicated that retinoids that could only induce either genomic, or non-genomic activities, were not strong promoters of neurite outgrowth, and that activities with respect to both transcriptional regulation and ERK1/2 phosphorylation produced maximum neurite outgrowth. These results suggest that the development of effective retinoids for clinical use will depend on the selection of compounds which have maximal activity in non-genomic as well as genomic assays.


Assuntos
Sistema de Sinalização das MAP Quinases , Crescimento Neuronal/efeitos dos fármacos , Retinoides/farmacologia , Transcriptoma , Linhagem Celular Tumoral , Humanos , Proteína Quinase 1 Ativada por Mitógeno/genética , Proteína Quinase 1 Ativada por Mitógeno/metabolismo , Proteína Quinase 3 Ativada por Mitógeno/genética , Proteína Quinase 3 Ativada por Mitógeno/metabolismo , Receptores do Ácido Retinoico/genética , Receptores do Ácido Retinoico/metabolismo
9.
Neuropeptides ; 64: 101-107, 2017 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-27866656

RESUMO

We have successfully used comparative genomics to identify putative regulatory elements within the human genome that contribute to the tissue specific expression of neuropeptides such as galanin and receptors such as CB1. However, a previous inability to rapidly delete these elements from the mouse genome has prevented optimal assessment of their function in-vivo. This has been solved using CAS9/CRISPR genome editing technology which uses a bacterial endonuclease called CAS9 that, in combination with specifically designed guide RNA (gRNA) molecules, cuts specific regions of the mouse genome. However, reports of "off target" effects, whereby the CAS9 endonuclease is able to cut sites other than those targeted, limits the appeal of this technology. We used cytoplasmic microinjection of gRNA and CAS9 mRNA into 1-cell mouse embryos to rapidly generate enhancer knockout mouse lines. The current study describes our analysis of the genomes of these enhancer knockout lines to detect possible off-target effects. Bioinformatic analysis was used to identify the most likely putative off-target sites and to design PCR primers that would amplify these sequences from genomic DNA of founder enhancer deletion mouse lines. Amplified DNA was then sequenced and blasted against the mouse genome sequence to detect off-target effects. Using this approach we were unable to detect any evidence of off-target effects in the genomes of three founder lines using any of the four gRNAs used in the analysis. This study suggests that the problem of off-target effects in transgenic mice have been exaggerated and that CAS9/CRISPR represents a highly effective and accurate method of deleting putative neuropeptide gene enhancer sequences from the mouse genome.


Assuntos
Sistemas CRISPR-Cas/genética , Expressão Gênica/genética , Neuropeptídeos/genética , RNA Guia de Cinetoplastídeos/genética , Animais , Sequência de Bases/genética , Biologia Computacional/métodos , DNA/genética , Endonucleases/genética , Deleção de Genes , Genoma , Camundongos
10.
Methods Mol Biol ; 1412: 57-63, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27245891

RESUMO

Displacement binding assays are nonfunctional assays mostly used with the aim of determining whether a certain compound (plant-derived or synthetic) is able to bind to a specific receptor with high affinity. Here, we describe the displacement binding assay that is carried out with a radioligand and CHO (Chinese Hamster Ovarian) cells stably transfected with the human cannabinoid CB2 receptor.


Assuntos
Ensaio Radioligante/métodos , Receptor CB2 de Canabinoide/metabolismo , Animais , Células CHO , Linhagem Celular , Cricetulus , Humanos , Ligantes , Ligação Proteica , Receptor CB2 de Canabinoide/agonistas , Receptor CB2 de Canabinoide/antagonistas & inibidores
11.
Methods Mol Biol ; 1412: 85-93, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27245894

RESUMO

The cyclic AMP assay is a functional assay that is commonly used to determine the pharmacological behavior (agonists, antagonists, inverse agonists) of G-protein-coupled receptor (GPCR) ligands. Here, we describe the cyclic AMP assay that is carried out with commercially available non-radioligand ready-to-use kits and Chinese hamster ovarian (CHO) cells stably transfected with the human cannabinoid CB2 receptor.


Assuntos
Bioensaio , AMP Cíclico/metabolismo , Receptor CB2 de Canabinoide/metabolismo , Animais , Células CHO , Linhagem Celular , Cricetulus , Expressão Gênica , Humanos , Receptor CB2 de Canabinoide/genética , Transfecção
12.
Handb Exp Pharmacol ; 231: 39-58, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26408157

RESUMO

Since the discovery of the two cannabinoid receptors, CB(1) and CB(2), several molecules, commonly defined as endocannabinoids, able to bind to and functionally activate these receptors, have been discovered and characterized. Although the general thought was that the endocannabinoids were mainly derivatives of the n-6 fatty acid arachidonic acid, recent data have shown that also derivatives (ethanolamides) of n-3 fatty acids may be classified as endocannabinoids. Whether the n-3 endocannabinoids follow the same biosynthetic and metabolic routes of the n-6 endocannabinoids is not yet clear and so warrants further investigation. In this review, we describe the primary biosynthetic and metabolic pathways for the two well-established endocannabinoids, anandamide and 2-arachidonoylglycerol.


Assuntos
Endocanabinoides/biossíntese , Amidoidrolases/metabolismo , Animais , Ácidos Araquidônicos/biossíntese , Glicerídeos/biossíntese , Humanos , Hidrólise , Monoacilglicerol Lipases/metabolismo , Alcamidas Poli-Insaturadas
13.
Proc Natl Acad Sci U S A ; 112(28): 8774-9, 2015 Jul 14.
Artigo em Inglês | MEDLINE | ID: mdl-26124120

RESUMO

Activation of the CB2 receptor is apparently an endogenous protective mechanism. Thus, it restrains inflammation and protects the skeleton against age-related bone loss. However, the endogenous cannabinoids, as well as Δ(9)-tetrahydrocannabinol, the main plant psychoactive constituent, activate both cannabinoid receptors, CB1 and CB2. HU-308 was among the first synthetic, selective CB2 agonists. HU-308 is antiosteoporotic and antiinflammatory. Here we show that the HU-308 enantiomer, designated HU-433, is 3-4 orders of magnitude more potent in osteoblast proliferation and osteoclast differentiation culture systems, as well as in mouse models, for the rescue of ovariectomy-induced bone loss and ear inflammation. HU-433 retains the HU-308 specificity for CB2, as shown by its failure to bind to the CB1 cannabinoid receptor, and has no activity in CB2-deficient cells and animals. Surprisingly, the CB2 binding affinity of HU-433 in terms of [(3)H]CP55,940 displacement and its effect on [(35)S]GTPγS accumulation is substantially lower compared with HU-308. A molecular-modeling analysis suggests that HU-433 and -308 have two different binding conformations within CB2, with one of them possibly responsible for the affinity difference, involving [(35)S]GTPγS and cAMP synthesis. Hence, different ligands may have different orientations relative to the same binding site. This situation questions the usefulness of universal radioligands for comparative binding studies. Moreover, orientation-targeted ligands have promising potential for the pharmacological activation of distinct processes.


Assuntos
Agonistas de Receptores de Canabinoides/farmacologia , Canabinoides/farmacologia , Receptor CB2 de Canabinoide/agonistas , Animais , Células CHO , Agonistas de Receptores de Canabinoides/química , Agonistas de Receptores de Canabinoides/metabolismo , Canabinoides/química , Canabinoides/metabolismo , Cricetinae , Cricetulus , Camundongos , Camundongos Endogâmicos C57BL , Estereoisomerismo
14.
Pharmacol Res ; 95-96: 82-91, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25836919

RESUMO

In isolated guinea-pig ileum (GPI), the A1-adenosine acute withdrawal response is under the control of several neuronal signalling systems, including the µ/κ-opioid and the cannabinoid CB1 systems. It is now well established that after the stimulation of the A1-adenosine system, the indirect activation of both µ/κ-opioid and CB1 systems is prevented by the peptide cholecystokinin-8 (CCk-8). In the present study, we have investigated the involvement of the Ca(2+)/ATP-activated K(+) channels in the regulation of both acute A1-withdrawal and CCk-8-induced contractures in the GPI preparation. Interestingly, we found that: (a) the A1-withdrawal contracture is inhibited by voltage dependent Ca(2+)-activated K(+) channels, Kv, while it is enhanced by the voltage independent Ca(2+)-activated K(+) channels, SKCa; (b) in the presence of CCk-8, the inhibitory effect of the A1 agonist, CPA, on the peptide induced contracture is significantly enhanced by the voltage independent Ca(2+)-activated K(+) channel, SKCa; and (c) the A1-withdrawal contracture precipitated in the presence of CCk-8 is controlled by the ATP-sensitive potassium channels, KATP. Our data suggest, for the first time, that both Ca(2+)- and ATP-activated K(+) channels are involved in the regulation of both A1-withdrawal precipitated and CCk-8 induced contractures.


Assuntos
Colecistocinina/farmacologia , Íleo/efeitos dos fármacos , Canais KATP/metabolismo , Contração Muscular/efeitos dos fármacos , Fragmentos de Peptídeos/farmacologia , Canais de Potássio Cálcio-Ativados/metabolismo , Receptor A1 de Adenosina/metabolismo , Receptores Opioides/metabolismo , Síndrome de Abstinência a Substâncias/fisiopatologia , Agonistas do Receptor A1 de Adenosina/farmacologia , Antagonistas do Receptor A1 de Adenosina/farmacologia , Animais , Cobaias , Íleo/metabolismo , Íleo/fisiopatologia , Técnicas In Vitro , Masculino , Antagonistas de Entorpecentes/farmacologia , Bloqueadores dos Canais de Potássio/farmacologia , Síndrome de Abstinência a Substâncias/tratamento farmacológico , Síndrome de Abstinência a Substâncias/metabolismo
15.
Br J Pharmacol ; 172(5): 1305-18, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25363799

RESUMO

BACKGROUND AND PURPOSE: This study aimed to address the questions of whether Δ(9)-tetrahydrocannabivarin (THCV) can (i) enhance activation of 5-HT1 A receptors in vitro and (ii) induce any apparent 5-HT1A receptor-mediated antipsychotic effects in vivo. EXPERIMENTAL APPROACH: In vitro studies investigated the effect of THCV on targeting by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) of 5-HT1A receptors in membranes obtained from rat brainstem or human 5-HT1A CHO cells, using [(35)S]-GTPγS and 8-[(3)H]-OH-DPAT binding assays. In vivo studies investigated whether THCV induces signs of 5-HT1A receptor-mediated antipsychotic effects in rats. KEY RESULTS: THCV (i) potently, albeit partially, displaced 8-[(3) H]-OH-DPAT from specific binding sites in rat brainstem membranes; (ii) at 100 nM, significantly enhanced 8-OH-DPAT-induced activation of receptors in these membranes; (iii) produced concentration-related increases in 8-[(3)H]-OH-DPAT binding to specific sites in membranes of human 5-HT1A receptor-transfected CHO cells; and (iv) at 100 nM, significantly enhanced 8-OH-DPAT-induced activation of these human 5-HT1A receptors. In phencyclidine-treated rats, THCV, like clozapine (i) reduced stereotyped behaviour; (ii) decreased time spent immobile in the forced swim test; and (iii) normalized hyperlocomotor activity, social behaviour and cognitive performance. Some of these effects were counteracted by the 5-HT1A receptor antagonist, WAY100635, or could be reproduced by the CB1 antagonist, AM251. CONCLUSIONS AND IMPLICATIONS: Our findings suggest that THCV can enhance 5-HT1A receptor activation, and that some of its apparent antipsychotic effects may depend on this enhancement. We conclude that THCV has therapeutic potential for ameliorating some of the negative, cognitive and positive symptoms of schizophrenia.


Assuntos
Antipsicóticos/farmacologia , Canabinoides/farmacologia , Dronabinol/análogos & derivados , Receptor 5-HT1A de Serotonina/metabolismo , Esquizofrenia/tratamento farmacológico , Animais , Antipsicóticos/química , Células CHO , Canabinoides/química , Cricetulus , Dronabinol/química , Dronabinol/farmacologia , Masculino , Dados de Sequência Molecular , Estrutura Molecular , Ratos , Ratos Sprague-Dawley , Psicologia do Esquizofrênico
16.
Bioorg Med Chem ; 22(17): 4770-83, 2014 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-25065940

RESUMO

In our ongoing program aimed at deeply investigating the endocannabinoid system (ES), a set of new alkyl-resorcinol derivatives was prepared focusing on the nature and the importance of the carboxamide functionality. Binding studies on CB1 and CB2 receptors, monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH) showed that some of the newly developed compounds behaved as very potent cannabinoid receptor ligands (Ki in the nanomolar range) while, however, none of them was able to inhibit MAGL and/or FAAH. Derivative 11 was a potent CB1 and CB2 ligand, with Ki values similar to WIN 55,212, exhibiting a CB1 and CB2 agonist profile in vitro. In the formalin test of peripheral acute and inflammatory pain in mice, this compound showed a weak and delayed antinociceptive effect against the second phase of the nocifensive response, exhibiting, interestingly, a quite potent transient receptor potential ankyrin type-1 (TRPA1) channel agonist activity. Moreover, derivative 14, characterized by lower affinity but higher CB2 selectivity than 11, proved to behave as a weak CB2 competitive inverse agonist.


Assuntos
Analgésicos/farmacologia , Proteínas do Tecido Nervoso/agonistas , Receptor CB1 de Canabinoide/agonistas , Receptor CB2 de Canabinoide/agonistas , Resorcinóis/farmacologia , Canais de Potencial de Receptor Transitório/agonistas , Analgésicos/síntese química , Analgésicos/química , Animais , Células CHO , Canais de Cálcio , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Cricetulus , Relação Dose-Resposta a Droga , Humanos , Ligantes , Masculino , Camundongos , Estrutura Molecular , Células NIH 3T3 , Nociceptividade/efeitos dos fármacos , Dor/tratamento farmacológico , Medição da Dor/efeitos dos fármacos , Resorcinóis/síntese química , Resorcinóis/química , Relação Estrutura-Atividade , Canal de Cátion TRPA1
17.
Artigo em Inglês | MEDLINE | ID: mdl-24303331

RESUMO

With the growing understanding of complex diseases, the focus of drug discovery has shifted from the well-accepted "one target, one drug" model designed towards a single target, to a new "multi-target, multidrug" model, aimed at systemically modulating multiple targets. In this context polypharmacology has emerged as a new paradigm to overcome the recent decline in pharmaceutical research and productivity. Likewise the networks are increasingly used as universal platforms to integrate the knowledge of a complex disease. A novel computational network-based approach for the identification of multicomponent synergy is hereafter proposed. Given a complex disease, the method exploits the topological features of the related network to identify possible combinations of hit targets. The best ranked combinations are subsequently selected based on a synergistic score. The results obtained on Type 2 Diabetes Mellitus highlight the ability of the method to retrieve novel target candidates related to the considered disease.

18.
J Biomed Inform ; 46(5): 876-81, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23850841

RESUMO

With the growing understanding of complex diseases, the focus of drug discovery has shifted from the well-accepted "one target, one drug" model, to a new "multi-target, multi-drug" model, aimed at systemically modulating multiple targets. In this context, polypharmacology has emerged as a new paradigm to overcome the recent decline in productivity of pharmaceutical research. However, finding methods to evaluate multicomponent therapeutics and ranking synergistic agent combinations is still a demanding task. At the same time, the data gathered on complex diseases has been progressively collected in public data and knowledge repositories, such as protein-protein interaction (PPI) databases. The PPI networks are increasingly used as universal platforms for data integration and analysis. A novel computational network-based approach for feasible and efficient identification of multicomponent synergistic agents is proposed in this paper. Given a complex disease, the method exploits the topological features of the related PPI network to identify possible combinations of hit targets. The best ranked combinations are subsequently computed on the basis of a synergistic score. We illustrate the potential of the method through a study on Type 2 Diabetes Mellitus. The results highlight its ability to retrieve novel target candidates, which role is also confirmed by the analysis of the related literature.


Assuntos
Quimioterapia Combinada , Humanos
19.
Br J Pharmacol ; 169(4): 887-99, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23711022

RESUMO

BACKGROUND AND PURPOSE: Although cannabinoid CB2 receptor ligands have been widely characterized in recombinant systems in vitro, little pharmacological characterization has been performed in tissues natively expressing CB2 receptors. The aim of this study was to compare the pharmacology of CB2 receptor ligands in tissue natively expressing CB2 receptors (human, rat and mouse spleen) and hCB2-transfected CHO cells. EXPERIMENTAL APPROACH: We tested the ability of well-known cannabinoid CB2 receptor ligands to stimulate or inhibit [³5S]GTPγS binding to mouse, rat and human spleen membranes and to hCB2-transfected CHO cell membranes. cAMP assays were also performed in hCB2-CHO cells. KEY RESULTS: The data presented demonstrate that: (i) CP 55,940, WIN 55,212-2 and JWH 133 behave as CB2 receptor full agonists both in spleen and hCB2-CHO cells, in both [³5S]GTPγS and cAMP assays; (ii) JWH 015 behaves as a low-efficacy agonist in spleen as well as in hCB2-CHO cells when tested in the [³5S]GTPγS assay, while it displays full agonism when tested in the cAMP assay using hCB2-CHO cells; (iii) (R)-AM 1241 and GW 405833 behave as agonists in the [³5S]GTPγS assay using spleen, instead it behaves as a low-efficacy inverse agonist in hCB2-CHO cells; and (iv) SR 144528, AM 630 and JTE 907 behave as CB2 receptor inverse agonists in all the tissues. CONCLUSION AND IMPLICATIONS: Our results demonstrate that CB2 receptor ligands can display differential pharmacology when assays are conducted in tissues that natively express CB2 receptors and imply that conclusions from recombinant CB2 receptors should be treated with caution.


Assuntos
Analgésicos/metabolismo , Agonistas de Receptores de Canabinoides/metabolismo , Receptor CB2 de Canabinoide/metabolismo , Baço/metabolismo , Analgésicos/farmacologia , Animais , Células CHO , Agonistas de Receptores de Canabinoides/farmacologia , Membrana Celular/metabolismo , Cricetulus , AMP Cíclico/metabolismo , Agonismo Inverso de Drogas , Guanosina 5'-O-(3-Tiotrifosfato)/metabolismo , Humanos , Ligantes , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Ratos , Ratos Wistar , Receptor CB2 de Canabinoide/agonistas , Receptor CB2 de Canabinoide/genética , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Reprodutibilidade dos Testes , Baço/efeitos dos fármacos
20.
Peptides ; 38(2): 418-26, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23059394

RESUMO

In isolated guinea-pig ileum (GPI), the κ-opioid acute withdrawal response is under the control of several neuronal signaling systems, including the µ-opioid, the A(1)-adenosine and the CB(1) receptors, which are involved in the inhibitory control of the κ-withdrawal response. After κ-opioid system stimulation, indirect activation of µ-opioid, A(1)-adenosine and CB(1) systems is prevented by the peptide cholecystokinin-8 (CCk-8). In the present study, we have investigated whether the NOP system is also involved in the regulation of the acute κ-withdrawal response. Interestingly, we found that in GPI preparation, the NOP system is not indirectly activated by the κ-opioid receptor stimulation, but instead this system is able by itself to directly regulate the acute κ-withdrawal response. Specifically, our results clearly highlight first the existence of an endogenous tone of the NOP system in GPI, and second that it behaves as a functional anti-opioid system. We also found that, the NOP receptor system is involved in the regulation of the CCk-8-induced contracture intensity, only when in the presence of the κ-opioid receptor stimulation. This effect seems to be regulated by an activation threshold mechanism. In conclusion, the NOP system could act as neuromodulatory system, whose action is strictly related to the modulation of both excitatory and inhibitory neurotransmitters released in GPI enteric nervous system.


Assuntos
Colecistocinina/farmacologia , Íleo/efeitos dos fármacos , Contração Muscular/efeitos dos fármacos , Fragmentos de Peptídeos/farmacologia , Receptores Opioides kappa/metabolismo , Receptores Opioides/metabolismo , Animais , Colecistocinina/metabolismo , Cobaias , Íleo/citologia , Íleo/metabolismo , Masculino , Antagonistas de Entorpecentes , Peptídeos Opioides/farmacologia , Fragmentos de Peptídeos/metabolismo , Receptores Opioides/agonistas , Relação Estrutura-Atividade , Receptor de Nociceptina , Nociceptina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...